FI943430A - Lääkkeenantojärjestelmä entsyymeillä ja valolle aktivoitavien lääkkeiden samanaikaiseksi vapauttamiseksi - Google Patents

Lääkkeenantojärjestelmä entsyymeillä ja valolle aktivoitavien lääkkeiden samanaikaiseksi vapauttamiseksi Download PDF

Info

Publication number
FI943430A
FI943430A FI943430A FI943430A FI943430A FI 943430 A FI943430 A FI 943430A FI 943430 A FI943430 A FI 943430A FI 943430 A FI943430 A FI 943430A FI 943430 A FI943430 A FI 943430A
Authority
FI
Finland
Prior art keywords
drug
attached
copolymeric
carrier
anticancer
Prior art date
Application number
FI943430A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI943430A0 (fi
Inventor
Jindrich Kopecek
Nancy Krinick
Original Assignee
Univ Utah
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah filed Critical Univ Utah
Publication of FI943430A0 publication Critical patent/FI943430A0/fi
Publication of FI943430A publication Critical patent/FI943430A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/811—Peptides or proteins is immobilized on, or in, an inorganic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y10S530/816—Attached to the carrier via a bridging agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Processing Of Solid Wastes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI943430A 1992-01-21 1994-07-20 Lääkkeenantojärjestelmä entsyymeillä ja valolle aktivoitavien lääkkeiden samanaikaiseksi vapauttamiseksi FI943430A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/822,924 US5258453A (en) 1992-01-21 1992-01-21 Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
PCT/US1993/000683 WO1993014142A1 (en) 1992-01-21 1993-01-21 Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light

Publications (2)

Publication Number Publication Date
FI943430A0 FI943430A0 (fi) 1994-07-20
FI943430A true FI943430A (fi) 1994-09-20

Family

ID=25237341

Family Applications (1)

Application Number Title Priority Date Filing Date
FI943430A FI943430A (fi) 1992-01-21 1994-07-20 Lääkkeenantojärjestelmä entsyymeillä ja valolle aktivoitavien lääkkeiden samanaikaiseksi vapauttamiseksi

Country Status (14)

Country Link
US (1) US5258453A (de)
EP (1) EP0621880B1 (de)
JP (1) JPH08500327A (de)
KR (1) KR100217186B1 (de)
AT (1) ATE184201T1 (de)
AU (1) AU663167B2 (de)
CA (1) CA2128330A1 (de)
DE (1) DE69326322T2 (de)
DK (1) DK0621880T3 (de)
FI (1) FI943430A (de)
HU (1) HUT68082A (de)
PL (1) PL172184B1 (de)
RU (1) RU94038047A (de)
WO (1) WO1993014142A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5482719A (en) * 1992-10-30 1996-01-09 Guillet; James E. Drug delivery systems
US20040071637A1 (en) * 1993-04-27 2004-04-15 Elia James P. Method for repairing a damaged portion of a human organ
US5449720A (en) * 1993-05-24 1995-09-12 Biotech Australia Pty Limited Amplification of the VB12 uptake system using polymers
GB9320781D0 (en) * 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
US5444650A (en) * 1994-01-25 1995-08-22 Nippondenso Co., Ltd. Semiconductor programmable read only memory device
US5599831A (en) * 1994-05-27 1997-02-04 Poretz; Ronald D. Method of preparation of pharmaceutical compositions
NO180167C (no) * 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
EP0820305A2 (de) * 1995-04-04 1998-01-28 Wound Healing of Oklahoma Krebsbehandlung durch photodynamische therapie, zusammen mit einem immunoadjuvans
US6316007B1 (en) 1995-04-04 2001-11-13 Wound Healing Of Oklahoma Combined physical and immunotherapy for cancer
US5776925A (en) * 1996-01-25 1998-07-07 Pharmacyclics, Inc. Methods for cancer chemosensitization
US6375930B2 (en) 1996-06-04 2002-04-23 Board Of Regents, The University Of Texas System Membrane incorporation of texaphyrins
US6493570B1 (en) 1998-11-02 2002-12-10 Photogen, Inc. Method for improved imaging and photodynamic therapy
CA2296056A1 (en) * 1997-07-10 1999-01-21 Keith Baker Methods for universally distributing therapeutic agents to the brain
US6251866B1 (en) * 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
JP2003516305A (ja) * 1997-08-05 2003-05-13 ワトソン ファーマシューティカルズ， インコーポレイテッド インターロイキン−２レセプターに標的化された結合体
US8974363B2 (en) 1997-12-11 2015-03-10 Provectus Pharmatech, Inc. Topical medicaments and methods for photodynamic treatment of disease
EP1044021B1 (de) 1998-01-05 2009-09-23 The University of Washington Erhöhter transport unter benutzung membranzerstörender stoffe
US6087952A (en) * 1998-03-06 2000-07-11 Mobile Information Systems, Inc. Remote mobile data suite and method
US6223071B1 (en) * 1998-05-01 2001-04-24 Dusa Pharmaceuticals Inc. Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light
US20030223978A1 (en) * 1998-05-22 2003-12-04 Nabi Ivan R. Conjugates of an AMF ligand and a cytotoxic molecule for use in cancer therapy
US8557298B2 (en) 1998-08-06 2013-10-15 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
US6986740B2 (en) * 1998-11-02 2006-01-17 Xantech Pharmaceuticals, Inc. Ultrasound contrast using halogenated xanthenes
US6222093B1 (en) * 1998-12-28 2001-04-24 Rosetta Inpharmatics, Inc. Methods for determining therapeutic index from gene expression profiles
US20030114366A1 (en) * 1999-01-11 2003-06-19 Francis J. Martin Microfabricated particles and method for treating solid tumors
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
WO2001036002A1 (en) * 1999-11-17 2001-05-25 School Of Pharmacy, University Of London Conjugates of hpma copolymer and ellipticin
WO2001051092A2 (en) * 2000-01-07 2001-07-19 University Of Washington Enhanced transport of agents using membrane disruptive agents
US6455073B1 (en) 2000-07-10 2002-09-24 Enzrel, Inc. Covalent microparticle-drug conjugates for biological targeting
US6454790B1 (en) * 2000-07-21 2002-09-24 Ceramoptec Industries, Inc. Treatment for Barrett's syndrome
BR0115795A (pt) 2000-11-29 2003-08-12 Pci Biotech As Métodos para introduzir uma molécula no citosol de uma célula, para o tratamento ou prevenção de uma doença, distúrbio ou infecção em um paciente, para estimular uma resposta imune, célula, e, uso de uma molécula de transferência e/ou um agente fotossensibilizante
EP1343531A2 (de) * 2000-12-21 2003-09-17 McGILL UNIVERSITY Konjugate von antikörpern und antikrebsmitteln
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7560424B2 (en) * 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
CA2445577C (en) * 2001-04-30 2012-07-03 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
US20040234497A1 (en) * 2001-05-04 2004-11-25 Yi Luo Hyaluronic acid containing bioconjugates:targeted delivery of anti-cancer drugs to cancer cells
AU2002332637A1 (en) * 2001-08-22 2003-03-10 Watson Pharmaceuticals, Inc. Conjugates targeted to target receptors
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
CA2822457C (en) 2001-12-14 2016-03-08 The University Of Wyoming Methods and compositions for controlled resease of drugs
US6846311B2 (en) * 2002-04-02 2005-01-25 Acueity, Inc. Method and apparatus for in VIVO treatment of mammary ducts by light induced fluorescence
US20050169883A1 (en) * 2002-05-06 2005-08-04 Prestwich Glenn D. Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
AU2003282683A1 (en) * 2002-10-04 2004-05-04 Photokinetix Inc. Photokinetic delivery of biologically active substances using pulsed incoherent light
US20050244400A1 (en) * 2004-02-10 2005-11-03 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
DK1737428T3 (en) * 2004-03-31 2017-10-09 Univ Utah Res Found MACROMOLECULAR ADMINISTRATION SYSTEMS FOR NON-INVASIVE IMAGING, EVALUATION AND TREATMENT OF ARTHRITIS AND OTHER INFLAMMATORY DISEASES
US20070287680A1 (en) * 2004-05-10 2007-12-13 University Of Utah Research Foundation Combined Active and Passive Targeting of Biologically Active Agents
US20090209508A1 (en) * 2005-05-16 2009-08-20 Universite De Geneve Compounds for Photochemotherapy
WO2007130465A2 (en) * 2006-05-02 2007-11-15 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
US7465312B2 (en) 2006-05-02 2008-12-16 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
US20090326435A1 (en) * 2006-05-02 2009-12-31 Green Medical, Inc. Systems and methods for treating superficial venous malformations like varicose or spider veins
WO2007143209A2 (en) * 2006-06-02 2007-12-13 University Of Virginia Patent Foundation Luminescent diketonate polymers
AU2007256780B2 (en) 2006-06-02 2013-08-29 President And Fellows Of Harvard College Protein surface remodeling
GB0618524D0 (en) 2006-09-20 2006-11-01 Isis Innovation Multimeric particles
WO2008063511A2 (en) * 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
EP2279210B1 (de) 2008-05-07 2017-04-12 BioMarin Pharmaceutical Inc. Auf lysosomen gerichtete peptide und ihre verwendung
EP2349347A2 (de) * 2008-10-07 2011-08-03 Rexahn Pharmaceuticals, Inc. Hpma-docetaxel- oder gemcitabin-konjugate und ihre verwendungen
KR20100083632A (ko) * 2009-01-14 2010-07-22 울산대학교 산학협력단 표적 단백질 분해효소 감응형 항암제 전구체
JP2012525146A (ja) * 2009-04-28 2012-10-22 プレジデント アンド フェロウズ オブ ハーバード カレッジ 細胞透過のための過剰に荷電されたタンパク質
EP2475376B1 (de) 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulierungen für lysosomale enzyme
KR20150058554A (ko) 2009-10-13 2015-05-28 렉산 파마슈티컬스, 인코포레이티드 항암제의 전달을 위한 폴리머 시스템
US8492339B2 (en) * 2009-10-26 2013-07-23 Empire Technology Development Llc Angiogenesis promoted by caged growth factors
WO2011112482A2 (en) 2010-03-08 2011-09-15 University Of Utah Research Foundation Polymeric drug delivery conjugates and methods of making and using thereof
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
WO2011150022A2 (en) 2010-05-25 2011-12-01 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
WO2012176023A1 (en) 2011-06-23 2012-12-27 Indian Institute Of Technology Kanpur Hydrogel scaffolds for tissue engineering
WO2013035750A1 (ja) * 2011-09-05 2013-03-14 Maeda Hiroshi 高分子型蛍光分子プローブ
EP3831393A1 (de) 2012-01-20 2021-06-09 Immunophotonics, Inc. Zusammensetzungen aus chitosan
US11773188B2 (en) 2012-01-20 2023-10-03 Immunophotonics, Inc Chitosan-derived compositions
ES2749746T3 (es) 2013-04-10 2020-03-23 Syndevrx Inc Inhibidores de fumagilol metap2 modificados o conjugados con polímeros para uso en el tratamiento de la obesidad
US20190002594A1 (en) 2014-07-16 2019-01-03 Immunophotonics, Inc. Chitosan-Derived Compositions
MX2018006904A (es) 2015-12-10 2018-08-24 Syndevrx Inc Derivados de fumagilol y polimorfos de los mismos.
CN114225045A (zh) 2016-01-11 2022-03-25 辛德弗雷克斯公司 代谢功能障碍引起的肿瘤的治疗
CA3028122A1 (en) 2016-06-16 2017-12-21 Oncoselect Therapeutics, Llc Porphyrin compounds and compositions useful for treating cancer
EP3612570A4 (de) 2017-04-17 2021-01-13 The University of Chicago Polymermaterialien zur abgabe kurzkettiger fettsäuren an den darm für anwendungen in der menschlichen gesundheit und behandlung von krankheiten
JP6894747B2 (ja) * 2017-04-19 2021-06-30 キヤノン株式会社 重合体
EP3870231A1 (de) 2018-10-26 2021-09-01 Syndevrx, Inc. Biomarker von metap2-inhibitoren und anwendungen davon

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3381105D1 (de) * 1982-08-12 1990-02-22 Kanegafuchi Chemical Ind Aktivierung biovertraeglicher terpolymere mit biologischen stoffen, deren anzubindende komplemente pathologische effektoren sind.
GB8500209D0 (en) * 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
EP0213811A3 (de) * 1985-08-16 1987-09-09 Johnson Matthey, Inc., Bakteriozin-gerichtete Verbindungen zur Krebstherapie

Also Published As

Publication number Publication date
EP0621880B1 (de) 1999-09-08
AU3593093A (en) 1993-08-03
RU94038047A (ru) 1996-06-10
DK0621880T3 (da) 1999-12-20
HU9402142D0 (en) 1994-09-28
US5258453A (en) 1993-11-02
EP0621880A1 (de) 1994-11-02
PL172184B1 (pl) 1997-08-29
EP0621880A4 (de) 1995-04-19
HUT68082A (en) 1995-05-29
DE69326322D1 (de) 1999-10-14
KR100217186B1 (ko) 1999-09-01
FI943430A0 (fi) 1994-07-20
AU663167B2 (en) 1995-09-28
WO1993014142A1 (en) 1993-07-22
DE69326322T2 (de) 2000-02-17
JPH08500327A (ja) 1996-01-16
ATE184201T1 (de) 1999-09-15
CA2128330A1 (en) 1993-07-22

Similar Documents

Publication Publication Date Title
FI943430A (fi) Lääkkeenantojärjestelmä entsyymeillä ja valolle aktivoitavien lääkkeiden samanaikaiseksi vapauttamiseksi
Aoshima et al. N 4-behenoyl-1-β-D-arabinofuranosylcytosine as a potential new antitumor agent
DE68918860D1 (de) Photoempfindliche mittel.
DK1137436T3 (da) Stimulering af T-celler mod selvantigener under anvendelse af CTLA-4-blokeringsmidler
CO5180590A1 (es) Derivados de camptotecina que tienen actividad anti tumores
ATE269089T1 (de) Verwendung von vitamin d derivaten zur verstärkung der wirkung von zytotoxischen stoffen
AU3468900A (en) Cyclodextrin polymers for use as drug carriers
HUT43948A (en) Emulsion compositions for dosing ionizable hydrophobic medical substances which are little soluble in water and process for preparing the same
WO2006113623A3 (en) Elimination of heterogeneous or mixed cell population in tumors
FI942878A (fi) Pyrofeoforbideja ja niiden käyttö valovaikutushoidossa
BRPI9809791B8 (pt) compostos imuno efetores de fosfato de aminoalquil glucosamina e composições compreendendo os mesmos
WO2004027045A3 (en) Polymer-linker-drug conjugates for targeted drug delivery
NO970990D0 (no) Implanterbare formlegemer for administrering av virkestoffer til planter
CN101820919A (zh) 用于局部药物输送的可注射聚合物-脂质共混物
WO1999022722A3 (en) Use of macrolides for the treatment of cancer and macular degeneration
CN1939316B (zh) 含阿霉素的微球及其制备方法
ES2376739T3 (es) Administración conjunta de un polisacárido con un agente quimioterapéutico para el tratamiento del cáncer
Bayley et al. Photoactivatable drugs
EP0838224A3 (de) Polymer - Arzneimittel Konjugate mit einer enzymspaltbaren Linker
CN109762099A (zh) 一种聚合物-抗肿瘤药物偶联物及其制备方法和用途
Říhová et al. Targetable photoactivalable drugs. 3. In vitro efficacy of polymer bound chlorin e6 toward human hepatocarcinoma cell line (PLC/PRF/5) targeted with galactosamine and to mouse splenocytes targeted with anti-Thy 1.2 antibodies
CA2382885A1 (en) Rhodamine derivatives for photodynamic diagnosis and treatment
CN104910277B (zh) 新型人源化抗cd22抗体-单甲基阿里他汀e偶联物及其制备方法
SE8601563D0 (sv) Matrismaterial, forfarande for framstellning derav och anvendning derav
BABA et al. Effective combination of anticancer drug with its antidote for chemotherapy of hepatic metastasis